Skip to main content
OpenTrials
Completed

NCT Number: NCT05320861

Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects

This single centre, open-label, non-randomised, single period, single-dose study in healthy male subjects was designed and conducted to assess the mass balance recovery, PK, metabolite profile and metabolite identification of SJP-0008.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

50 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Quotient Sciences

Ruddington, Nottingham, NG11 6JS, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
  • Must be willing and able to communicate and participate in the whole study
  • Must have regular bowel movements
  • Must provide written informed consent
  • Must agree to adhere to the contraception requirements of the protocol

Exclusion criteria

  • Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
  • Subjects who are, or are immediate family members of, a study site or sponsor employee
  • Subjects who report to have previously received SJP-0008
  • Evidence of current SARS-CoV-2 infection
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week
  • A confirmed positive alcohol breath test at screening or admission
  • Current smokers and those who have smoked within the last 6 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 6 months
  • Subjects with pregnant or lactating partners
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study

Other protocol-defined exclusion criteria may apply

Treatment and study plan

[14C]SJP-0008

Drug

Single oral dose of [14C]SJP-0008

Primary outcomes

  1. Mass balance recovery of total radioactivity in all excreta after a single oral dose of [14C]SJP-0008

    Time frame: Until the mass balance criteria for all participants have been met (estimated up to Day 10)

    Mass balance recovery of total radioactivity in all excreta by analysing the total radioactivity and metabolic profile in plasma, urine and faeces samples.

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of SJP-0008 and SNJ-2026

    Time frame: Up to Day 8

  2. Area under the concentration-time curve from time zero to last measurable concentration (AUC0-last) of SJP-0008 and SNJ-2026

    Time frame: Up to Day 8

  3. Area under concentration-time curve from time zero to infinity (AUC0-inf) of SJP-0008 and SNJ-2026

    Time frame: Up to Day 8

  4. Area under the concentration-time curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) of SJP-0008 and SNJ-2026

    Time frame: Up to Day 8

  5. Time to maximum plasma concentration (Tmax) of SJP-0008 and SNJ-2026

    Time frame: Up to Day 8

  6. Half-life (T1/2) of SJP-0008 and SNJ-2026

    Time frame: Up to Day 8

  7. First order rate constant associated with the terminal (log-linear) portion of the curve (Lambda-z) of SJP-0008 and SNJ-2026

    Time frame: Up to Day 8

  8. Percentage of participants with adverse events (AEs)

    Time frame: Until the mass balance criteria for all participants have been met (estimated up to Day 10)

Sponsors and collaborators

Lead sponsor

Senju Pharmaceutical Co., Ltd.

Industry

Collaborators

  • Quotient Sciences

Registry information

Official study title

A Single Dose Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]SJP-0008 in Healthy Male Subjects After an Oral Dose

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Apr 11, 2022
Registry last updated
Apr 11, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.